Journal of Nuclear Medicine · 2018 · 26 citations · 33 references
MedicineNuclear MedicineRadiologyBone MetabolismBone ScintigraphyMetastasisBone MetastasisBone Metastasis ImagingFluoride MetabolismMetastatic Bone DiseaseMetastatic Breast CancerPositron Emission TomographyBone Metastasis Response AssessmentBreast Cancer Bone Metastasis ImagingFluoride Metabolism In BoneFluoride Positron Emission TomographyIncremental Diagnostic ValueMonitoring Therapy ResponseNoninvasive DiagnosticsRadionuclide Bone Imaging
Our purpose was to establish whether noninvasive measurement of changes in <sup>18</sup>F-fluoride metabolic flux to bone mineral (K<sub>i</sub>) by PET/CT can provide incremental value in response assessment of bone metastases in breast cancer compared with SUV<sub>max</sub> and SUV<sub>mean</sub>. <b>Methods:</b> Twelve breast cancer patients starting endocrine treatment for de novo or progressive bone metastases were included. Static <sup>18</sup>F-fluoride PET/CT scans were acquired 60 min after injection, before and 8 wk after commencing treatment. Venous blood samples were taken at 55 and 85 min after injection to measure plasma <sup>18</sup>F-fluoride activity concentrations, and K<sub>i</sub> in individual bone metastases was calculated using a previously validated method. Percentage changes in K<sub>i</sub>, SUV<sub>max</sub>, and SUV<sub>mean</sub> were calculated from the same index lesions (≤5 lesions) from each patient. Clinical response up to 24 wk, assessed in consensus by 2 experienced oncologists masked to PET imaging findings, was used as a reference standard. <b>Results:</b> Of the 4 patients with clinically progressive disease (PD), mean K<sub>i</sub> significantly increased (>25%) in all, SUV<sub>max</sub> in 3, and SUV<sub>mean</sub> in 2. Of the 8 non-PD patients, K<sub>i</sub> decreased or remained stable in 7, SUV<sub>max</sub> in 5, and SUV<sub>mean</sub> in 6. A significant mean percentage increase from baseline for K<sub>i</sub>, compared with SUV<sub>max</sub> and SUV<sub>mean</sub>, occurred in the 4 patients with PD (89.7% vs. 41.8% and 43.5%, respectively; <i>P</i> < 0.001). <b>Conclusion:</b> After 8 wk of endocrine treatment for bone-predominant metastatic breast cancer, K<sub>i</sub> more reliably differentiated PD from non-PD than did SUV<sub>max</sub> and SUV<sub>mean</sub>, probably because measurement of SUV underestimates fluoride clearance by not considering changes in input function.
33
Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET.
Randall A. Hawkins, Yong Choi, Sung-Cheng Huang et al. · PubMed · 1992 · 386 citations
Kewei Chen, Daniel Bandy, Eric M. Reiman et al. · Journal of Cerebral Blood Flow & Metabolism · 1998 · 258 citations